iBio names endocrinologist Molly Carr as chief medical officer

iBio, Inc. (NASDAQ: IBIO) announced on August 4, 2026 that effective July 31, 2026, Molly Carr, M.D. was appointed as the Chief Medical Officer of iBio, Inc.¹ Dr. Carr, age 59, is described as a physician executive with extensive experience in the biotechnology and pharmaceutical industries.¹

Most recently, she served as Clinical Head, Associate Vice President, Insulin and Glucagon Franchise at Eli Lilly and Company since 2021, overseeing clinical development activities for Eli Lilly's insulin and glucagon portfolio, including late-stage development programs for efsitora, a once-weekly insulin candidate, as well as other diabetes and metabolic disease therapies.¹ Before that role, she served as Senior Medical Fellow, Associate Vice President, Diabetes Business Development and External Innovation at Eli Lilly from 2018 to 2021, where she led evaluation of external business development opportunities and supported licensing and strategic transactions in diabetes and related metabolic diseases.¹ Her earlier career included roles at GlaxoSmithKline plc, CSL Behring, Wyeth LLC, and academic appointments at Northwestern University, the University of Washington, and the University of Pennsylvania.¹ She holds a B.A. in Biology from Barnard College and an M.D. from Columbia College of Physicians and Surgeons, and is board certified in Endocrinology, Diabetes and Metabolism and Internal Medicine.¹

Under her employment agreement dated July 31, 2026, Dr. Carr will receive an annual base salary of $470,000 and will be eligible for an annual target cash bonus equal to 40% of her base salary.¹ The company also approved a non-qualified stock option award to purchase 430,000 shares, granted on July 31, 2026, with an exercise price equal to the closing price on the grant date, a ten-year term, vesting 25% after one year and the remaining 75% over 36 monthly installments.¹

Severance terms provide that if terminated without cause or for good reason, she would receive nine months of base salary continuation, a pro rata bonus, and nine months of COBRA coverage¹, with enhanced terms tied to a change-in-control event as described in the filing.